A Framework to Predict the Molecular Classification and Prognosis of Breast Cancer Patients and Characterize the Landscape of Immune Cell Infiltration

Figure 5

Integrative analysis of immune-cell infiltration (ICI) scores on drug response. Heatmap of immune-related genes in different ICI score groups. The immune-related genes were divided into two groups: (a) gene set 1 and (b) gene set 2. The ICI cluster, ICI gene cluster, PAM50 subtype, age, tumor stage, and survival status were used as patient annotations. (c) Differences in neoantigen between high or low ICI score groups. (d) Comparison of drug sensitivity in high or low ICI score groups (Wilcoxon’s test, ). The box plots show the differences in IC50 values for the top 12 drugs sorted by value. (e) Boxplot for the distribution of ICI scores of patients in different anti-PD-L1 therapeutic responses in IMvigor210 cohort (Wilcoxon’s test, ). (f) Survival analysis for high or low ICI score groups in IMvigor210 cohort patients using Kaplan-Meier curves. The log-rank test showed that . (g) Bar graph showing the proportion of patients with various clinical responses (responder: complete response (CR)/partial response (PR); nonresponder: stable disease (SD)/progressive disease (PD)) to anti-PD-L1 immunotherapy in the high or low ICI score groups of the IMvigor210 cohort.

(a)

(b)

(c)

(d)

(e)

(f)

(g)